745 related articles for article (PubMed ID: 33811817)
1. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
Jentsch PC; Anand M; Bauch CT
Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
[TBL] [Abstract][Full Text] [Related]
2. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.
Moore S; Hill EM; Tildesley MJ; Dyson L; Keeling MJ
Lancet Infect Dis; 2021 Jun; 21(6):793-802. PubMed ID: 33743847
[TBL] [Abstract][Full Text] [Related]
3. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
4. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
[TBL] [Abstract][Full Text] [Related]
5. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
6. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
[TBL] [Abstract][Full Text] [Related]
7. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
8. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
[TBL] [Abstract][Full Text] [Related]
9. Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study.
Foy BH; Wahl B; Mehta K; Shet A; Menon GI; Britto C
Int J Infect Dis; 2021 Feb; 103():431-438. PubMed ID: 33388436
[TBL] [Abstract][Full Text] [Related]
10. Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.
Milne GJ; Carrivick J; Whyatt D
BMC Med; 2022 Feb; 20(1):80. PubMed ID: 35177062
[TBL] [Abstract][Full Text] [Related]
11. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
12. The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022).
Willem L; Abrams S; Franco N; Coletti P; Libin PJK; Wambua J; Couvreur S; André E; Wenseleers T; Mao Z; Torneri A; Faes C; Beutels P; Hens N
BMC Public Health; 2024 Apr; 24(1):1171. PubMed ID: 38671366
[TBL] [Abstract][Full Text] [Related]
13. Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study.
Diarra M; Kebir A; Talla C; Barry A; Faye J; Louati D; Opatowski L; Diop M; ; White LJ; Loucoubar C; Miled SB
BMJ Glob Health; 2022 Feb; 7(2):. PubMed ID: 35193893
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
[TBL] [Abstract][Full Text] [Related]
16. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
MacIntyre CR; Costantino V; Trent M
Vaccine; 2022 Apr; 40(17):2506-2513. PubMed ID: 33958223
[TBL] [Abstract][Full Text] [Related]
17. Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study.
Imai N; Rawson T; Knock ES; Sonabend R; Elmaci Y; Perez-Guzman PN; Whittles LK; Kanapram DT; Gaythorpe KAM; Hinsley W; Djaafara BA; Wang H; Fraser K; FitzJohn RG; Hogan AB; Doohan P; Ghani AC; Ferguson NM; Baguelin M; Cori A
Lancet Public Health; 2023 Mar; 8(3):e174-e183. PubMed ID: 36774945
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
20. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
Hogan AB; Winskill P; Watson OJ; Walker PGT; Whittaker C; Baguelin M; Brazeau NF; Charles GD; Gaythorpe KAM; Hamlet A; Knock E; Laydon DJ; Lees JA; Løchen A; Verity R; Whittles LK; Muhib F; Hauck K; Ferguson NM; Ghani AC
Vaccine; 2021 May; 39(22):2995-3006. PubMed ID: 33933313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
